Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.
Written informed consent to participate
At least 18 years of age
High and very high risk patients as assessed by the physician suffering from documented primary hypercholesterolemia or mixed dyslipidemia at start of bempedoic acid treatment
bempedoic acid added to ezetimibe and rosuvastatin or atorvastatin,
Patients who have received PCSK9i monoclonal antibody treatment in the last 3 months before the start of the triple therapy exposure
Patients who have ever received PCSK9i-siRNA treatment